Nathan Ona

Nathan Ona

Auto-generated profile, based on publicly available information

Nathan Ona

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DZDapeng Zhang
Dapeng Zhang
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
DMDevendra Surendrakumar Maurya
Devendra Surendrakumar Maurya
NHNing Huang
Ning Huang
QXQi Xiao
Qi Xiao
VPVirgil Percec
Virgil Percec

21 October 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DZDapeng Zhang
Dapeng Zhang
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
DMDevendra Surendrakumar Maurya
Devendra Surendrakumar Maurya
MLMatthew Liu
Matthew Liu
QXQi Xiao
Qi Xiao
VPVirgil Percec
Virgil Percec

21 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJaclynn A. Meshanni
Jaclynn A. Meshanni
ESEmily R. Stevenson
Emily R. Stevenson
DZDapeng Zhang
Dapeng Zhang
RSRachel Sun
Rachel Sun
NONathan A. Ona
Nathan A. Ona
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
Current clinical strategies for the delivery of pulmonary therapeutics to the lung are primarily targeted to the upper portions of the airways, such as treatment with nebulized instillation and inhalation. However, targeted delivery to the lower regions of the lung is necessary for the treatment of parenchymal lung injury and disease. Here, we show the development of an mRNA therapeutic for the lower lung in mice using one-component Ionizable Amphiphilic Janus Dendrimers as a delivery vehicle. We deliver an anti-inflammatory cytokine mRNA, transforming growth factor-beta, to produce transient protein expression in the lower regions of the lung. This study highlights a method for precise, effective, and safe delivery of TGF-β mRNA to the lung in mice. This delivery system offers a promising approach for targeting therapeutics to the specific tissues, a strategy necessary to fill the current clinical gap in treating parenchymal lung injury and disease.

13 June 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MAMahwish Arshad
Mahwish Arshad
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
DMDevendra Surendrakumar Maurya
Devendra Surendrakumar Maurya
JLJuncheng Lu
Juncheng Lu
NONathan Ona
Nathan Ona
VPVirgil Percec
Virgil Percec

17 December 2024 in Biomacromolecules
Verified
Journal Article
Closed access
Dipankar SahooDipankar Sahoo
Dipankar Sahoo
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
JLJuncheng Lu
Juncheng Lu
DMDevendra Surendrakumar Maurya
Devendra Surendrakumar Maurya
NONathan Ona
Nathan Ona
VPVirgil Percec
Virgil Percec

27 March 2026 in Science Advances
Verified
Journal Article
Open access
NONathan A. Ona
Nathan A. Ona
DZDapeng Zhang
Dapeng Zhang
LLLisa Lindesmith
Lisa Lindesmith
WPWook-Jin Park
Wook-Jin Park
JMJaclynn A. Meshanni
Jaclynn A. Meshanni
EAElena N. Atochina-Vasserman
Elena N. Atochina-Vasserman
There have been rapid advances in nucleoside-modified messenger RNA–based vaccines, particularly during the SARS-CoV-2 pandemic, demonstrating a rapid and cost-effective approach for addressing infectious diseases. A major challenge remains in developing a delivery system that protects mRNA from degradation and facilitates its passage through tissue and cellular barriers. Current four-component lipid nanoparticles enable efficient endosomal escape and are a pivotal technology for the delivery of mRNA vaccines. However, challenges such as stability, availability, durability, and adverse effects persist. We have developed a self-assembling one-component ionizable amphiphilic Janus dendrimers (IAJD) delivery system with naturally occurring amino heads, capable of efficiently delivering mRNA to the spleen and lymph nodes. This single-component system simplifies synthesis, reduces development complexity, and enables rapid global distribution of mRNA vaccines during pandemics. As a proof of concept, one-component IAJD97, formulated with mRNA encoding norovirus mRNA capsid protein, demonstrates the potential of IAJDs as efficient delivery platform for mRNA vaccines, advancing their effectiveness and expanding applications to improve public health outcomes.